Abstract:Context: Decades-old beliefs regarding androgens and prostate cancer (PCa) have undergone dramatic shifts in light of modern evidence and new theoretical constructs, but considerable confusion remains on this topic, particularly with regard to the use of testosterone therapy in men with any history of PCa. Objective: To review current literature regarding the relationship of serum testosterone on PCa and in particular the effect of testosterone therapy on PCa progression and recurrence. Evidence acquisition: A Medline search was conducted to identify all original and review articles assessing the effect of androgens on the prostate and the use of testosterone in men with a history of treated and untreated PCa. Evidence synthesis: Contrary to traditional teaching, high endogenous serum testosterone does not increase the risk of developing PCa, and low serum testosterone does not protect against PCa. Although limited in size and duration, current studies similarly fail to indicate any increased risk of PCa in men receiving testosterone therapy. These results indicate a finite ability of androgens to stimulate PCa growth (the saturation model). A majority of studies demonstrate an association between low serum testosterone and poor prognostic features of PCa, including high-grade disease, advanced pathologic stage, and increased risk of biochemical recurrence following radical prostatectomy. The prostate-specific antigen-to-testosterone ratio predicted PCa risk in several biopsy studies. Multiple reports of testosterone therapy in men after treatment for localized PCa have shown low or absent recurrence rates. Some men with untreated PCa have received testosterone therapy without evidence for PCa progression. Conclusions: The long-held belief that PCa risk is related to high serum androgen concentrations can no longer be supported. Current evidence indicates that maximal androgen-stimulated PCa growth is achieved at relatively low serum testosterone concentrations. It may therefore be reasonable to consider testosterone therapy in selected men with PCa and symptomatic hypogonadism.

Mechanistic targets for BPH and prostate cancer–a review

Common biological factors implicated in benign prostatic hyperplasia and prostate cancer, conventional and phytotherapeutic approaches employed in management: A review

Pathophysiology of Benign Prostatic Hyperplasia and Benign Prostatic Enlargement: A Mini-Review

The role of the androgen receptor in prostate development and benign prostatic hyperplasia: A review

Benign prostatic hyperplasia – what do we know?

The role of prostatic inflammation in the development and progression of benign and malignant diseases

Targeting signaling pathways in prostate cancer: mechanisms and clinical trials

Therapies Targeted to Androgen Receptor Signaling Axis in Prostate Cancer: Progress, Challenges, and Hope

The Molecular Basis and Clinical Consequences of Chronic Inflammation in Prostatic Diseases: Prostatitis, Benign Prostatic Hyperplasia, and Prostate Cancer

Immune Cell Proinflammatory Microenvironment and Androgen-Related Metabolic Regulation During Benign Prostatic Hyperplasia in Aging

Current Understanding of Androgen Signaling in Prostatitis and its Treatment: A Review

Prostate cancer microenvironment: multidimensional regulation of immune cells, vascular system, stromal cells, and microbiota

Molecular Mechanisms of Prostate Cancer Development in the Precision Medicine Era: A Comprehensive Review

Sex hormone-binding globulin and its critical role in prostate cancer: A comprehensive review

Mechanism of Androgen-Independent Stromal Proliferation in Benign Prostatic Hyperplasia

Identification Of Key Genes And Pathways In Benign Prostatic Hyperplasia

The Etiology and Pathogenesis of Benign Prostatic Hyperplasia: The Roles of Sex Hormones and Anatomy

Androgen Signaling in Prostate Cancer: When a Friend Turns Foe

Recent advances and future perspectives in the therapeutics of prostate cancer

Prostate Cancer: Emerging Modifiable Risk Factors and Therapeutic Strategies in the Management of Advanced Cancer

A new era of testosterone and prostate cancer: from physiology to clinical implications